《新股消息》據報精鋒醫療科技擬來港上市 集資最多3億美元
據《IFR》引述消息人士指,深圳市精鋒醫療科技計劃今年內來港上市,集資約2億至3億美元。精鋒醫療科技日前已向聯交所提交上市申請,聯席保薦人為摩根士丹利、中金公司及花旗。
初步招股資料顯示,精鋒醫療科技主要從事設計、開發、製造和商業化手術機器人,目前已啟動多孔及單孔腔鏡手術機器人的關鍵性臨床試驗,中國首家、全球僅有的兩家公司之一。公司並已完成精鋒(R)多孔腔鏡手術機器人MP1000及精鋒(R)單孔腔鏡手術機器人SP1000的設計及主要研發,兩項產品均具備通過綠色通道進行國家藥監局有關創新醫療器械的快速審查資格。
精鋒醫療科技過去兩個年度未有錄得收入,去年度虧損達到3.49億元人民幣,較2020年的虧損7,936.6萬元人民幣擴大。
公司預期,來港上市集資所得將用於產品研發和日後後製造與商業化;以及用於手術機器人行業及相關領域的潛在策略收購、投資或合作等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.